Catalyst

Slingshot members are tracking this event:

Ziopharm (ZIOP) to complete Phase 1 trial of Allogeneic CD19-Specific T Cells From Peripheral Blood in HSCT patients by December 2016 - On Hold

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
XON

100%
ZIOP

100%

Additional Information

Additional Relevant Details Update on June 18 2018: FDA put the trial on hold.
http://ir.ziopharm.c...
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Study, Allogeneic Hematopoietic Stem Cell Transplant, Cd19, Engineered T-cells, Leukemia, Lymphoma, Hsct, Open-label, Single Arm Study